These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 8750139)
1. New strategies for the application of high-dose chemotherapy with haematopoietic support in paediatric solid tumours. Hartmann O Ann Oncol; 1995; 6 Suppl 4():13-6. PubMed ID: 8750139 [TBL] [Abstract][Full Text] [Related]
2. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy. Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891 [TBL] [Abstract][Full Text] [Related]
4. Haematological support of high-dose sequential chemotherapy: clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. Tarella C; Gavarotti P; Caracciolo D; Corradini P; Cherasco C; Castellino C; Gallo E; Pileri A Ann Oncol; 1995; 6 Suppl 4():3-8. PubMed ID: 8750137 [TBL] [Abstract][Full Text] [Related]
5. Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia. Frampton JE; Faulds D Pharmacoeconomics; 1996 Jan; 9(1):76-96. PubMed ID: 10161371 [TBL] [Abstract][Full Text] [Related]
6. Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. Frampton JE; Lee CR; Faulds D Drugs; 1994 Nov; 48(5):731-60. PubMed ID: 7530630 [TBL] [Abstract][Full Text] [Related]
7. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Schmitz N; Dreger P; Zander AR; Ehninger G; Wandt H; Fauser AA; Kolb HJ; Zumsprekel A; Martin A; Hecht T Bone Marrow Transplant; 1995 Feb; 15(2):261-6. PubMed ID: 7539668 [TBL] [Abstract][Full Text] [Related]
8. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118 [TBL] [Abstract][Full Text] [Related]
9. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma. Ossenkoppele GJ; Jonkhoff AR; Huijgens PC; Nauta JJ; van der Hem KG; Dräger AM; Langenhuijsen MM Bone Marrow Transplant; 1994 Jan; 13(1):37-41. PubMed ID: 7517255 [TBL] [Abstract][Full Text] [Related]
10. Colony-stimulating factors for the management of neutropenia in cancer patients. Dale DC Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591 [TBL] [Abstract][Full Text] [Related]
11. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C; Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116 [TBL] [Abstract][Full Text] [Related]
13. [Hematopoietic growth factors in the prevention of infections complications in children with hematologic-oncologic diseases]. Lehrnbecher T Klin Padiatr; 2001 Sep; 213 Suppl 1():A88-102. PubMed ID: 11577368 [TBL] [Abstract][Full Text] [Related]
14. Treatment of aggressive non-Hodgkin's lymphoma with chemotherapy in combination with filgrastim. Schriber J Drugs; 2002; 62 Suppl 1():33-46. PubMed ID: 12479593 [TBL] [Abstract][Full Text] [Related]
15. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings. Frampton JE; Yarker YE; Goa KL Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335 [TBL] [Abstract][Full Text] [Related]
16. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation. Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941 [TBL] [Abstract][Full Text] [Related]
17. [Hematopoietic growth factors in prophylaxis and therapy of infections complications in children with neutropenia]. Lehrnbecher T Klin Padiatr; 2001; 213(4):212-38. PubMed ID: 11528556 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies. Sheridan WP; Begley CG; To LB; Grigg A; Szer J; Maher D; Green MD; Rowlings PA; McGrath KM; Cebon J Bone Marrow Transplant; 1994 Jul; 14(1):105-11. PubMed ID: 7524904 [TBL] [Abstract][Full Text] [Related]